About Teikoku Seiyaku
About
News
-
- 2026.4.27
- Announcement of License Agreement for KTP-001 (Recombinant Human Matrix Metalloproteinase-7), a Protein Preparation Designed to Induce Spontaneous Regression of Lumbar Disc Herniation
-
- 2026.3.31
- Change in The Board of Directors
-
- 2025.12.19
- Announcement of Sales Partnership Agreement in Japan for New Osteoarthritis Treatment Agent
-
- 2025.6.11
- Promotion of joint educational activities on knee osteoarthritis
-
- 2025.3.27
- Change in The Board of Directors
Company
Since our foundation over 170 years ago, Teikoku Seiyaku has used the transdermal technology we have cultivated to respond to and anticipate the needs of both patients and medical professionals.
View More














